Federico Rolando Bonanni

Dr. Federico Rolando Bonanni

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Lazio, Italy
orcid
Main research interest is diabetes and metabolism, with a fo...

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
Marco MeloniMarco Meloni
Marco Meloni
LULuigi Uccioli
Luigi Uccioli
AAAikaterini Andreadi
Aikaterini Andreadi
LGLaura Giurato
Laura Giurato
VRValeria Ruotolo
Valeria Ruotolo
DLDavide Lauro
Davide Lauro
Aim: The study aimed to evaluate the rate and causes of major amputation in patients with diabetic foot syndrome. Methods: The current study is a retrospective observational study including consecutive patients referred to a tertiary-level diabetic foot service from January 2020 to November 2023 due to a new diabetic foot problem requiring hospital admission. All patients had been managed by a multi-disciplinary diabetic foot team (MDFT) through a pre-set limb salvage protocol including the management of peripheral arterial disease, infection, foot offloading, and comorbidities. At 1 year of follow-up, the following outcomes measures were evaluated: rate of major amputation, clinical characteristics of amputees, and causes of major amputation. Results: Overall, 1226 patients referring for a diabetic foot problem and requiring hospitalization were screened for the study. Among them, 30 (2.4%) patients experienced major amputation. Amputees had 69.9±10.7 years, the majority were male (73.3%) with a prevalence of type 2 diabetes (93.3%) and a long diabetes duration (25.2±9.8 years). They showed several comorbidities such as ischaemic heart disease (83.3%), heart failure (46.7%), end-stage-renal-disease (26.7%), and in addition high rate of peripheral arterial disease (PAD) (86.7%), infected wounds (98.3%), and osteomyelitis (90%). Major amputation was mainly related to untreatable limb ischemia (failure of revascularization procedure) in 56.7% of cases, calcaneus osteomyelitis and necrotizing fasciitis in 16.7% of cases, and tarsal osteomyelitis in 10% of cases. Conclusions: The rate of major amputation was very low in this population managed by a MDFT. PAD was the main cause of major amputation.

27 May 2025 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
Marco MeloniMarco Meloni
Marco Meloni
EBErmanno Bellizzi
Ermanno Bellizzi
LULuigi Uccioli
Luigi Uccioli
LGLaura Giurato
Laura Giurato
VRValeria Ruotolo
Valeria Ruotolo
DLDavide Lauro
Davide Lauro
Aim: Peripheral blood mononuclear cells (PB-MNCs) therapy is an adjuvant treatment for patients with ischaemic diabetic foot ulcers (DFUs) and no-option critical limb ischemia (NO-CLI). This study aimed to evaluate factors influencing the effectiveness of PB-MNC therapy. Method: This prospective, not controlled study included a cohort of patients with DFUs and NO-CLI treated by PB-MNCs. NO-CLI was defined as the revascularization failure with desert foot (absence of any artery below-the-ankle) or partial desert foot (absence of a wound-related artery with TcPO 2 < 30 mmHg) at the final post-procedural angiogram. After one year of follow-up, the rate of major amputation was evaluated such as clinical, wound, and vascular features of amputees in comparison to not amputees. In addition, the factors influencing the risk of major amputation were analyzed. Results/discussion: Sixty-four patients were included. The mean age was 73.8 ± 5.8 years, 75% were male, and all of them had type 2 diabetes. At one year of follow-up, major amputation was documented in 12.5% of patients. Amputees had a higher rate of desert foot (vs. partial desert foot) (100% vs. 25%, p < 0.0001), higher post-procedural pain (5.7 ± 1.9 vs. 2.2 ± 1.3, p < 0.0001), lower TcPO 2 after PB-MNCs therapy (30 ± 8 vs. 43 ± 8 mmHg, p = 0.0001), and more cases of heel ulcers (75% vs. 21.4%, p = 0.002). Independent predictors of major amputation resulted the presence of desert foot, persistence of post-procedural pain, heel involvement with multiple ulcers, and inability to stand or walk without assistance. Conclusion: PB-MNCs therapy resulted less effective in patients with complete desert foot, persistence of paint after therapy, heel involvement in persons with multiple ulcers, and impaired walking.

28 April 2025 in The International Journal of Lower Extremity Wounds
Verified
Journal Article
Closed access
MSMartina Salvi
Martina Salvi
Marco MeloniMarco Meloni
Marco Meloni
Federico Rolando BonanniFederico Rolando Bonanni
Federico Rolando Bonanni
EBErmanno Bellizzi
Ermanno Bellizzi
VRValeria Ruotolo
Valeria Ruotolo
DLDavide Lauro
Davide Lauro
The current study aimed to evaluate the clinical outcomes of patients admitted for diabetic foot ulcers (DFUs) located in the heel. The study is a retrospective observational study including a population of patients admitted for DFUs from April 2024 to September 2024. According to the wound location, patients were divided in two groups: those with heel ulcers and those with forefoot/midfoot ulcers without calcaneal involvement. All patients have been managed through a limb salvage protocol in the respect of international guidelines. The following hospital outcomes were evaluated: minor and major amputation, mortality, length of stay, need for regenerative surgery by using dermal-epidermal graft. Overall, 150 patients were included. The mean age was 70.2 ± 12.2 years, most patients were male (76.0%), had type 2 diabetes (92.7%) with a mean duration of 22.1±13.2 years; 27 (18%) patients had heel ulcers, while 123 (82%) had forefoot/midfoot lesions. Outcomes for patients with heel location and without were: minor amputation (18.5 vs 32.5%, p = 0.1), major amputation (7.4 vs 0.8%, p = 0.02), mortality (0 vs 0.8%, p = 0.5), length of hospital stay (17.5 ± 8.5 vs 14.4 ± 8.7 days, p = 0.08), need for regenerative therapy using dermal-epidermal substitutes (48.1 vs 19.5%, p = 0.003) respectively. In addition, heel ulcer was found to be an independent predictor for major amputation [OR 5.06, CI95% (3.1–11.4), p = 0.02] and length of stay [OR 6 CI95% (3.6–10.9), p = 0.003]. In patients admitted for DFUs, wounds located in the heel were associated to an increased risk of major amputation, need for regenerative therapy and length of stay (even though in the limit of statistical difference) than wounds not located in the heel. These data underline the need for tailored management strategies in this high-risk subgroup of patients.

28 March 2025 in The International Journal of Lower Extremity Wounds
Verified
Journal Article
Closed access
Federico Rolando BonanniFederico Rolando Bonanni
Federico Rolando Bonanni
Marco MeloniMarco Meloni
Marco Meloni
MSMartina Salvi
Martina Salvi
EBErmanno Bellizzi
Ermanno Bellizzi
VRValeria Ruotolo
Valeria Ruotolo
DLDavide Lauro
Davide Lauro
The current study aimed to evaluate characteristics and outcomes of patients admitted for a diabetic foot attack (DFA). It is a retrospective observational study including a population of patients admitted for diabetic foot ulcers (DFU) in a specialized diabetic foot service. Based on the type of hospital admission (emergency or elective), patients were divided into two groups: those with DFA and those without DFA (chronic diabetic foot, CDF). The DFA was considered in case of ischemia, infection and Charcot foot requiring urgent hospitalization. The following in-hospital outcomes were evaluated: minor and major amputation, number of surgical procedures, length of stay (LOS), mortality. Overall, 150 patients were included. The mean age was 70.3 ± 12.2 years, most patients were male (76.0%) and had type 2 diabetes (92.7%) with a mean duration of 22.1 ± 13.2 years; 88 (58.7%) patients presented DFA while 62 (41.3%) presented CDF. The DFA group reported a greater rate of foot infection (81.8 vs 50.0%, p = 0.002), higher HbA1c values (67.9 ± 22 vs 56.6 ± 14.3 mmol/mol, p = 0.0005) and more cases of first assessment for DFUs (43.2 vs 12.9%, p = 0.005) compared with the CDF group. Outcomes for DFA and CDF were minor amputation (36.4 vs 21%, p = 0.04), major amputation (2.3 vs 1.6%, p = 0.7), need for surgical procedures (>1) (27.3 vs 11.3%, p = 0.0001), LOS (17 ± 9.6 vs 12 ± 6.3 days, p = 0.0004), mortality (1.1 vs 0%, p = 0.6). In addition, foot infection and poor glycometabolic control were independently related to the DFA presentation. The DFA increases the risk of minor amputations, more surgical procedures and longer hospitalization. Foot infection and poor metabolic control resulted closely related to the DFA.

29 September 2025 in The International Journal of Lower Extremity Wounds
Verified
Journal Article
Closed access
MSMartina Salvi
Martina Salvi
Federico Rolando BonanniFederico Rolando Bonanni
Federico Rolando Bonanni
LULuigi Uccioli
Luigi Uccioli
EBErmanno Bellizzi
Ermanno Bellizzi
VRValeria Ruotolo
Valeria Ruotolo
Marco MeloniMarco Meloni
Marco Meloni
The current study aimed to evaluate the outcomes of heel diabetic foot osteomyelitis (DFO) managed in a specialized diabetic foot service. The research is a single-center retrospective observational study including a population of patients with diabetic foot ulcers (DFUs) complicated by DFO and requiring hospitalization, managed between 2019 and 2022 in a tertiary level diabetic foot service. According to the location of bone infection, patients were divided into two groups: those with heel DFO and those with forefoot/midfoot DFO. After one year of follow-up, the following outcomes were evaluated and compared between groups: healing, healing time, major amputation, and mortality. Overall, 114 patients were included. The mean age was 67.9 ± 12, most of them were male (72.8%) and had type 2 diabetes (91.2%); 84 (73.7%) of patients reported forefoot/midfoot DFO, while 30 (26.3%) reported heel DFO. Patients with heel DFO showed greater rates of soft tissue infection (80 vs 68.7%, p = 0.04), ulcer size >5 cm (93.3 vs 34.3%, p = <0.0001), gangrene (63.3 vs 22.9%, p = <0.0001), higher C-reactive protein values (67.6 ± 25 vs 24 ± 16 mg/dl, p = 0.0002) and concomitant peripheral arterial disease (PAD) (83.3 vs 52.4%, p = 0.0002). Outcomes for heel DFO and forefoot/midfoot DFO were: wound healing (66.7 vs 97%, p = <0.0001), healing time (14 ± 6 vs 6.8 ± 5 weeks, p=<0.0001), major amputation (10 vs 0%, p = 0.0002), and mortality (6.6 vs 4.8%, p = 0.3) respectively. At the multivariate logistic regression analysis, heel DFO [OR 8.4, CI95% (2.1–14.8), p=<0.0001] and PAD [OR 3.5, CI95% (1.1–4.2), p = 0.001] were independent predictors of major amputation, while heel DFO [OR 6.8, CI95% (1.9–10.5), p=<0.0001], PAD [OR 4.8, CI95% (1.4–7.6), p = 0.0001], and ulcer size [OR 1.5, CI95% (1.2–2.6), p=<0.0001] were independent predictors of non-healing. Heel DFO resulted associated with a higher risk of major amputation and reduced chance of healing.

7 August 2025 in The International Journal of Lower Extremity Wounds
Verified
Journal Article
Closed access
Federico Rolando BonanniFederico Rolando Bonanni
Federico Rolando Bonanni
Marco MeloniMarco Meloni
Marco Meloni
MSMartina Salvi
Martina Salvi
EBErmanno Bellizzi
Ermanno Bellizzi
ABAurora Buccolini
Aurora Buccolini
DLDavide Lauro
Davide Lauro
The study aimed to evaluate the mid-term outcomes of patients admitted for a diabetic foot attack (DFA). It is a retrospective observational study including a population of patients admitted for diabetic foot ulcers (DFUs) into a specialized multidisciplinary diabetic foot service. Based on the type of hospital admission (emergency or elective), patients were divided into two groups: those with DFA and those without DFA (chronic diabetic foot, CDF). The DFA was considered in case of ischemia (acute or chronic), infection and Charcot foot requiring urgent hospitalization. Once discharged, patients were regularly followed as outpatients with the following six-month outcomes: healing; major amputation; mortality; hospital readmission; non-fatal major adverse limb and cardiovascular events (MALCE) including nonfatal myocardial infarction (MI), nonfatal stroke, and limb ischemia requiring revascularization. Overall, 141 patients were included. The mean age was 70 ± 12 years, most patients were male (76.6%) and had type 2 diabetes (93.6%) with a mean duration of 22 ± 13 years; 81 (57.4%) patients presented DFA while 60 (42.6%) presented CDF. No cases of admitted Charcot foot were recorded. The DFA group reported 81.5% cases of severe/moderate infections, while the CDF group presented 50% of mild infections. The DFA group reported higher HbA1c values (67 ± 22 vs 56 ± 14 mmol/mol, p = 0.0008) and more cases of first assessment for DFUs (59.3 vs 13.3%, p < 0.0001) when compared to the CDF group. The six-month follow-up outcomes for DFA and CDF were: healing (65.4 vs 60.0%, p = 0.3); major amputation (4.9 vs 1.7%, p = 0.2); mortality (8.6 vs 11.7%, p = 0.5); hospital readmission (27.2 vs 26.7%, p = 0.8); non-fatal MALCE (9.9 vs 23.3%, p = 0.1). Six-month outcomes did not show significant differences between the DFA and CDF groups in terms of healing, major amputation, mortality, readmission, and non-fatal MALCE. Adequate management of DFA seems to ensure favourable mid-term outcomes, even if compared to patients with CDF.